A Pipeline for Drug Target Identification and Validation.

Area of Science:

• Oncology
• Genomics
• Molecular Biology

Background:

• Tumor profiling generates vast genomic data, driving new cancer therapy development.
• Targeting oncogenic lesions shows success but faces limitations in direct inhibition efficacy and transient benefits.
• Functional genomics identifies cancer vulnerabilities, but in vivo target validation requires assessing tumor growth impact and toxicity.

Purpose of the Study:

• To present an RNA interference (RNAi) pipeline for cancer target discovery and validation.
• To detail the use of optimized short-hairpin RNA (shRNA) tools for negative selection screens.
• To highlight an inducible RNAi platform combined with embryonic stem cell (ESC)-based genetically engineered mouse models (GEMMs) for in vivo validation.

Main Methods:

• Development of an RNA interference (RNAi) pipeline for cancer target discovery.
• Utilization of optimized short-hairpin RNA (shRNA) tools for negative selection screens.
• Implementation of an inducible RNAi platform integrated with ESC-based GEMMs for in vivo target validation.

Main Results:

• The pipeline facilitates deep in vivo target validation.
• Optimized shRNA tools enable effective negative selection screens.
• The inducible RNAi platform combined with GEMMs allows comprehensive assessment of target inhibition in vivo.

Conclusions:

• The described RNAi pipeline offers a robust approach for cancer target discovery.
• This method enables thorough in vivo validation of potential cancer targets.
• The integrated system aids in identifying effective and safe cancer therapies by assessing both efficacy and toxicity.